Ignite Creation Date:
2025-12-25 @ 12:05 AM
Ignite Modification Date:
2026-01-05 @ 6:54 PM
Study NCT ID:
NCT05103358
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-03
First Post:
2021-10-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Sponsor:
Aadi Bioscience, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Tumor | View |
| None | Tumor, Solid | View |
| None | Metastasis | View |
| None | Metastatic Cancer | View |
| None | Cancer | View |
| None | Cancer Metastatic | View |
| None | Tumors | View |
| None | Neoplasms | View |
| None | Neoplasm Metastasis | View |
| None | Solid Tumor | View |
| None | Advanced Solid Tumor | View |
| None | Advanced Cancer | View |
| None | Malignant Solid Tumor | View |
| None | Malignant Solid Neoplasm | View |
| None | Malignant Neoplasm | View |
| None | Malignant Tumor | View |
| None | TSC | View |
| None | TSC1 | View |
| None | TSC2 | View |
| None | Metastatic Solid Tumor | View |
| None | Metastatic Neoplasm | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | TSC1 gene | View |
| None | TSC2 gene | View |
| None | Tissue agnostic | View |
| None | Basket | View |
| None | nab-sirolimus | View |
| None | mTOR inhibitor | View |
| None | nanoparticle albumin bound | View |
| None | mammalian target of rapamycin | View |
| None | mechanistic target of rapamycin | View |
| None | tumor profile | View |
| None | tuberous sclerosis complex 1 | View |
| None | tuberous sclerosis complex 2 | View |
| None | mTOR | View |
| None | sirolimus | View |
| None | TSC1 | View |
| None | TSC2 | View |
| None | ABI-009 | View |
| None | FYARRO | View |
| None | Precision | View |
| None | Precision 1 | View |
| None | Pathogenic alterations | View |
| None | Pathogenic mutations | View |
| None | Inactivating mutations | View |